Atea Pharmaceuticals, Inc.
Clinical-stage biopharma developing oral antiviral therapies for serious viral diseases.
AVIR | US
Overview
Corporate Details
- ISIN(s):
- US04683R1068
- LEI:
- Country:
- United States of America
- Address:
- 225 FRANKLIN STREET, 2110 BOSTON
- Website:
- https://ateapharma.com/
- Sector:
- Manufacturing
Description
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company leverages its expertise in virology, medicinal chemistry, and biology to develop direct-acting antivirals for single-stranded ribonucleic acid (ssRNA) viruses. Atea's lead program is a combination regimen of bemnifosbuvir (a nucleotide analog polymerase inhibitor) and ruzasvir (an NS5A inhibitor) for the treatment of Hepatitis C Virus (HCV). This oral, pan-genotypic regimen is currently in a global Phase 3 development program, aiming to address unmet medical needs for patients with HCV.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Atea Pharmaceuticals, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Atea Pharmaceuticals, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Atea Pharmaceuticals, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
